May 10, 2021
Arcturus Therapeutics Announces First Quarter 2021 Company Overview and Financial Results and Provides New Clinical Data
May 3, 2021
Arcturus Therapeutics to Report First Quarter 2021 Financial Results and Provide Corporate Update on May 10, 2021
March 30, 2021
Arcturus Therapeutics to Present at Upcoming Investor and Scientific Conferences
Arcturus Therapeutics Partnerships
In October 2017, Arcturus entered into a partnership with Janssen, a Johnson & Johnson company, to develop and commercialize nucleic acid-based drug products for the treatment of specified diseases, including HBV, using Arcturus’ LUNAR lipid-mediated delivery platform and UNA oligomer chemistry. Under the agreement, facilitated by J&J Innovation, Arcturus received an upfront cash payment and will receive R&D support, as well as pre-clinical, development, and sales milestone payments, and royalty payments on any future licensed product sales. Janssen will assume responsibility for development costs and all commercialization costs associated with the program.
In December 2016, Arcturus entered into a partnership with Takeda to develop RNA-based therapeutic candidates for the treatment of NASH and other GI-related disorders, utilizing Arcturus’ wholly-owned therapeutic delivery platform, LUNAR, and UNA oligomer chemistry.
LUNAR-RPL (Replicon RNA)
In October 2017, Arcturus entered into a research collaboration and worldwide license agreement with Synthetic Genomics Inc., to develop self-amplifying RNA-based vaccines and therapeutics in both human and animal health. The collaboration will bring together Arcturus’ LUNAR® lipid-mediated delivery platform with Synthetic Genomics’ RNA replicon platform to potentially enable more efficacious and lower cost vaccines and therapeutics.
LUNAR-GSD3 and LUNAR-RARE
In October 2015, Arcturus has partnered with Ultragenyx Pharmaceutical, Inc. to develop RNA medicines that treat rare and ultra-rare diseases. This collaboration combines Arcturus’ expertise in RNA medicines with Ultragenyx’ proven ability in rare disease drug development. In this partnership, Arcturus is exploiting the versatility of our proprietary unlocked nucleomonomer agent (UNA) Oligomer chemistry and Lipid-enabled and Unlocked Nucleic Acid modified RNA (LUNAR®) lipid-mediated delivery platform to design and optimize mRNA medicines for rare disease targets. These medicines will be developed and commercialized by Ultragenyx.